Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 86.76 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; calcium carbonate; magnesium stearate; polysorbate 80; hyprolose; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 43.38 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: polysorbate 80; lactose monohydrate; hyprolose; croscarmellose sodium; euphorbia antisyphilitica; magnesium stearate; calcium carbonate; microcrystalline cellulose; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 21.69 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium carbonate; polysorbate 80; croscarmellose sodium; hyprolose; microcrystalline cellulose; lactose monohydrate; euphorbia antisyphilitica; titanium dioxide; macrogol 8000; hypromellose; purified talc; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 10.845 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium carbonate; lactose monohydrate; croscarmellose sodium; hyprolose; microcrystalline cellulose; polysorbate 80; euphorbia antisyphilitica; titanium dioxide; macrogol 8000; hypromellose; purified talc; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Israel - English - Ministry of Health

medison pharma ltd - pasireotide as embonate - powder and solvent for suspension for injection - pasireotide as embonate 20 mg/vial - pasireotide - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Israel - English - Ministry of Health

medison pharma ltd - pasireotide as embonate - powder and solvent for suspension for injection - pasireotide as embonate 40 mg/vial - pasireotide - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Israel - English - Ministry of Health

medison pharma ltd - pasireotide as embonate - powder and solvent for suspension for injection - pasireotide as embonate 60 mg/vial - pasireotide - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - dexchlorpheniramine maleate 2mg;  ; dexchlorpheniramine maleate 2mg - film coated tablet - 2 mg - active: dexchlorpheniramine maleate 2mg   excipient: lactose monohydrate magnesium stearate maize starch starch active: dexchlorpheniramine maleate 2mg excipient: lactose monohydrate magnesium stearate maize starch starch

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - dexchlorpheniramine maleate 0.4 mg/ml;   - syrup - 2 mg/5ml - active: dexchlorpheniramine maleate 0.4 mg/ml   excipient: apricot flavour 15502857 blood orange flavour sc481962 ethanol menthol methyl hydroxybenzoate ponceau 4r propyl hydroxybenzoate purified water sodium chloride sodium citrate dihydrate sorbitol sucrose - hayfever and year round allergies: sneezing, watery itchy eyes itchy skin from hives, insect bites.

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - canakinumab - powder, for solution - 150mg - canakinumab 150mg